Merck & Co., Inc. $MRK Shares Acquired by DKRT Investments Corp.

Key Points

• DKRT Investments increased its Merck stake by 160% in Q3, buying 20,000 shares to hold 32,500 shares valued at about $2.73 million, making MRK its 21st-largest position (~0.7% of the fund).
• Merck beat quarterly estimates with $2.04 EPS and $16.40 billion in revenue, set FY2026 EPS guidance of 5.00–5.15, and carries a Wall Street consensus of "Moderate Buy" with an average target of $125.88.
• The company announced a $0.85 quarterly dividend (annualized $3.40, yield 2.9%; ex-dividend Mar 16, payable Apr 7), while insiders sold roughly 320,176 shares (~$38.3M) last quarter, leaving insiders owning about 0.13% of the stock.

DKRT Investments Corp. increased its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 160.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 32,500 shares of the company's stock after buying an additional 20,000 shares during the quarter. Merck & Co., Inc. comprises about 0.7% of DKRT Investments Corp.'s holdings, making the stock its 21st largest position. DKRT Investments Corp.'s holdings in Merck & Co., Inc. were worth $2,728,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in MRK. Brighton Jones LLC increased its holdings in shares of Merck & Co., Inc. by 29.5% in the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company's stock valued at $3,808,000 after purchasing an additional 8,710 shares during the period. Sivia Capital Partners LLC lifted its holdings in shares of Merck & Co., Inc. by 52.2% during the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company's stock worth $910,000 after purchasing an additional 3,941 shares during the period. SouthState Corp lifted its holdings in shares of Merck & Co., Inc. by 4.2% during the second quarter. SouthState Corp now owns 35,682 shares of the company's stock worth $2,825,000 after purchasing an additional 1,436 shares during the period. Souders Financial Advisors grew its position in Merck & Co., Inc. by 118.6% in the 2nd quarter. Souders Financial Advisors now owns 5,884 shares of the company's stock valued at $466,000 after buying an additional 3,192 shares during the last quarter. Finally, OneAscent Wealth Management LLC grew its position in Merck & Co., Inc. by 21.5% in the 2nd quarter. OneAscent Wealth Management LLC now owns 5,199 shares of the company's stock valued at $412,000 after buying an additional 920 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company's stock.

Merck & Co., Inc. Stock Down 0.2%

Merck & Co., Inc. stock opened at $115.85 on Friday. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $125.14. The firm has a market capitalization of $286.43 billion, a price-to-earnings ratio of 15.91, a price-to-earnings-growth ratio of 2.24 and a beta of 0.27. The stock's fifty day moving average is $114.20 and its two-hundred day moving average is $98.51. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The business had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. During the same quarter in the previous year, the company posted $1.72 EPS. The business's revenue was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Analysts predict that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be given a dividend of $0.85 per share. The ex-dividend date is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. Merck & Co., Inc.'s payout ratio is presently 46.70%.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Weiss Ratings reissued a "hold (c)" rating on shares of Merck & Co., Inc. in a research note on Monday, December 29th. UBS Group lifted their target price on shares of Merck & Co., Inc. from $105.00 to $130.00 and gave the company a "buy" rating in a report on Wednesday, January 7th. The Goldman Sachs Group boosted their price target on shares of Merck & Co., Inc. from $92.00 to $120.00 and gave the stock a "buy" rating in a research note on Tuesday, December 2nd. Citigroup increased their price target on shares of Merck & Co., Inc. from $115.00 to $120.00 and gave the stock a "neutral" rating in a report on Wednesday, February 4th. Finally, Guggenheim raised their price objective on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the company a "buy" rating in a research report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $125.88.

Insider Activity at Merck & Co., Inc.

In other Merck & Co., Inc. news, CEO Robert M. Davis sold 47,434 shares of the company's stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $118.04, for a total value of $5,599,109.36. Following the sale, the chief executive officer owned 443,602 shares of the company's stock, valued at $52,362,780.08. This represents a 9.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Chirfi Guindo sold 20,000 shares of the stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $121.88, for a total transaction of $2,437,600.00. Following the completion of the sale, the chief marketing officer owned 80,615 shares in the company, valued at $9,825,356.20. This represents a 19.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 320,176 shares of company stock valued at $38,281,735 in the last quarter. 0.13% of the stock is owned by corporate insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.